$184.710
0.000 (0.00%)Zum Schluss
- Hoch
- 184.710
- Eröffnung
- 184.710
- Volumengewichteter Durchschnittskurs
- —
- Volumen
- 0.00
- Marktkap.
- 16.51B
- Tief
- 184.710
- Umsatz
- 0.00
- EV/EBITDA, TTM
- -26.64
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Analystenbewertungen (7)
JP Morgan
$317
2025-04-21
JP Morgan
2025-04-21
Kursziel
$317
Guggenheim
—
2025-04-16
Guggenheim
2025-04-16
Kursziel
—
Guggenheim
$348
2025-04-10
Guggenheim
2025-04-10
Kursziel
$348
RBC Capital
$312
2025-04-07
RBC Capital
2025-04-07
Kursziel
$312
Citizens Capital Markets
$348
2025-02-28
Citizens Capital Markets
2025-02-28
Kursziel
$348
Bewertungskennzahlen
Event-Zeitleiste
News
6.009-18CNBCMajor Analyst Recommendations for Thursday: Nvidia, Apple, Meta, Coinbase, Alphabet, Nike, CSX, Abercrombie & Fitch, and Others
6.004-07CNBCHere are Monday's biggest analyst calls: Nvidia, Apple, Tesla, Netflix, Bank of America, Meta, Reddit, Microsoft & more
9.003-31NewsfilterBeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
9.003-05BusinesswireTEVIMBRA ist in den USA für die Erstlinienbehandlung von fortgeschrittenem Plattenepithelkarzinom der Speiseröhre in Kombination mit Chemotherapie zugelassen
9.003-04BusinesswireSamenvatting: TEVIMBRA goedgekeurd in de VS voor eerstelijns behandeling van gevorderd oesofageaal plaveiselcelcarcinoom in combinatie met chemotherapie
BGNE FAQ – beantwortet von Alphio AI
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
7 analysts cover BGNE: 6 rate it Buy, 1 Hold and 0 Sell.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.